Insights into the Global Gastroparesis Market - Epidemiology Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Gastroparesis - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical and forecasted Gastroparesis epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastroparesis, which is a translated meaning of stomach paralysis, is a digestive disorder characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach, resulting in the cardinal symptoms of early satiety, postprandial fullness, nausea, vomiting, belching and bloating. It is now recognized as part of a broader spectrum of gastric neuromuscular dysfunction that includes impaired gastric accommodation. The overlap between the symptoms, of Gastroparesis and other disorders such as functional dyspepsia makes the diagnosis of Gastroparesis.

Gastroparesis may be idiopathic or associated with diabetes mellitus, may occur after a medical intervention (iatrogenic or post-surgical), or with neurological disorders, it can also occur after a viral or bacterial infection, such as Salmonella gastroenteritis. Interestingly, Helicobacter pylori infection of the stomach does not seem to influence gastric emptying or accommodation but may be associated with heightened sensitivity in patients with functional dyspepsia.

According to the American Diabetes Association, Gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes, in which the stomach takes too long to empty its contents (delayed gastric emptying). The vagus nerve controls the movement of food through the digestive tract. If this nerve is damaged or stops working, the muscles of the stomach and intestines do not work normally, and the movement of food is slowed or stopped. Just as with other types of neuropathy, diabetes can damage the vagus nerve if blood glucose levels remain high over a long period. High blood glucose causes chemical changes in nerves and damages the blood vessels that carry oxygen and nutrients to the nerves.

Gastroparesis Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalence of Gastroparesis, Gender-specific Prevalence of Gastroparesis, Severity-specific Prevalence of Gastroparesis, Type-specific Prevalence of Gastroparesis and Total Diagnosed Prevalent Population of Gastroparesis a scenario of Gastroparesis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Reasons to Buy

1. Develop business strategies by understanding the trends shaping and driving the 7MM Gastroparesis market.
2. Quantify patient populations in the 7MM Gastroparesis market to improve product design, pricing, and launch plans.
3. Organize sales and marketing efforts by identifying the specific type of Gastroparesis that presents the best opportunities for Gastroparesis therapeutics in each of the markets covered.
4. The Gastroparesis epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
5. The proprietary Gastroparesis epidemiology model is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Gastroparesis Detailed Epidemiology Segmentation

• The total prevalent population of gastroparesis in the 7MM is expected to rise from 33,690,400 in 2017.
• As per estimates, the highest prevalence of gastroparesis was observed in the United States with 13,019,321 cases in 2017, which is likely to rise by 2030.
• As per the analysis, a higher percentage of prevalence was observed for females, in comparison to males, in all the 7MM countries.
• According to the analysis, it has been observed that mild cases are more prominent in comparison to moderate-to-severe. In the United States, 7,811,592 mild cases were observed in 2017, i.e., 60% of the gastroparesis patient pool. Additionally, moderate-to-severe accounted for 40% of the gastroparesis patient pool.
• Among the major types of gastroparesis, i.e., idiopathic, diabetic and post-surgical gastroparesis, idiopathic gastroparesis accounts for a higher number of gastroparesis cases.
• Among the EU5 countries, in 2017, Germany had the highest prevalent population of gastroparesis followed by Spain and Italy. On the other hand, the United Kingdom had the lowest prevalent population of Gastroparesis.

Scope of the Report

• The report covers the descriptive overview of Gastroparesis, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Gastroparesis.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Gastroparesis, Total Diagnosed and Treated Cases of Gastroparesis.

Report Highlights

• Eleven-Year Forecast of Gastroparesis
• 7MM Coverage
• Total Prevalence of Gastroparesis
• Gender-specific Prevalence of Gastroparesis
• Severity-specific Prevalence of Gastroparesis
• Type-specific Prevalence of Gastroparesis and
• Total Diagnosed Prevalent Population of Gastroparesis

Key Questions Answered

• What is the disease risk, burden and unmet needs of Gastroparesis?
• What is the historical Gastroparesis patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Gastroparesis at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Gastroparesis?
• Out of the countries mentioned above, which country would have the highest prevalent population of Gastroparesis during the forecast period (2020-2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

For more information about this report visit https://www.researchandmarkets.com/r/yrfl5q